TABLE 1.
Characteristics of patients with spinal metastasis from primary BC.
| Characteristic | Training cohort (n = 74) | Validation cohort (n = 36) | Training cohort (n = 74) | Validation cohort (n = 36) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High Ki-67 (n = 48) | Low Ki-67 (n = 26) | P | High Ki-67 (n = 18) | Low Ki-67 (n = 18) | P | HER-2 positive (n = 25) | HER-2 negative (n = 49) | P | HER-2 positive (n = 15) | HER-2 negative (n = 21) | P | |
| Age (Mean ± SD) | 54.48 ± 9.76 | 54.31 ± 9.06 | *0.004 | 52.50 ± 9.22 | 49.06 ± 9.51 | *0.006 | 49.73 ± 11.82 | 53.90 ± 8.70 | *0.043 | 49.01 ± 9.23 | 56.57 ± 10.01 | 0.625 |
| Menopausal status, No (%) | 1.000 | 1.000 | 1.000 | 0.138 | ||||||||
| Premenopausal | 7 (63.64) | 4 (36.36) | 3 (50.00) | 3 (50.00) | 4 (33.33) | 8 (66.67) | 4 (80.00) | 1 (20.00) | ||||
| Postmenopausal | 41 (65.08) | 22 (34.92) | 15 (50.00) | 15 (50.00) | 21 (33.87) | 41 (66.13) | 11 (35.48) | 20 (64.52) | ||||
| Family history, No (%) | 1.000 | 1.000 | 0.547 | 1.000 | ||||||||
| Yes | 1 (50. 00) | 1 (50.00) | 0 (0.00) | 1 (100.00) | 0 (0.00) | 2 (100.00) | 0 (0.00) | 1 (100.00) | ||||
| No | 47 (65.28) | 25 (34.72) | 18 (51.43) | 17 (48.57) | 25 (34.72) | 47 (65.28) | 15 (42.86) | 20 (57.14) | ||||
| LNM, No (%) | 0.773 | 1.000 | 0.358 | 0.443 | ||||||||
| Yes | 34 (62.96) | 20 (37.04) | 12 (50.00) | 12 (50.00) | 15 (29.41) | 36 (70.59) | 10 (37.04) | 17 (62.96) | ||||
| No | 14 (70.00) | 6 (30.00) | 6 (50.00) | 6 (50.00) | 10 (43.48) | 13 (56.52) | 5 (55.56) | 4 (44.44) | ||||
| ER, No (%) | 0.064 | 0.443 | 0.113 | 0.260 | ||||||||
| Positive | 27 (56.25) | 21 (43.75) | 12 (44.44) | 15 (55.56) | 13 (26.53) | 36 (73.47) | 9 (34.62) | 17 (65.38) | ||||
| Negative | 21 (80.77) | 5 (19.23) | 6 (66.67) | 3 (33.33) | 12 (48.00) | 13 (52.00) | 6 (60.00) | 4 (40.00) | ||||
| PR, No (%) | 0.165 | 0.499 | 0.072 | 0.864 | ||||||||
| Positive | 20 (55.56) | 16 (44.44) | 9 (42.86) | 12 (57.14) | 8 (22.22) | 28 (77.78) | 8 (38.10) | 13 (61.90) | ||||
| Negative | 28 (73.68) | 10 (26.32) | 9 (60.00) | 6 (40.00) | 17 (44.74) | 21 (55.26) | 7 (46.67) | 8 (53.33) | ||||
| Histological grade, No (%) | 0.166 | 0.309 | 0.609 | 0.957 | ||||||||
| Ⅰ | 0 (0.00) | 1 (100.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (100.00) | 0 (0.00) | 0 (0.00) | ||||
| Ⅱ | 40 (63.49) | 23 (36.51) | 15 (46.87) | 17 (53.13) | 23 (35.94) | 41 (64.06) | 13 (41.94) | 18 (58.06) | ||||
| Ⅲ | 8 (80.00) | 2 (20.00) | 3 (75.00) | 1 (25.00) | 2 (22.22) | 7 (77.78) | 2 (40.00) | 3 (60.00) | ||||
HER-2, human epidermal growth factor receptor 2; Ki-67, antigen identified by monoclonal antibody; SD, standard deviation; LNM, lymph node metastasis; ER, estrogen receptor; PR, progesterone receptor.
*Statistically significant values of p < 0.05.